Company Profile:

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Recent News:

On Apr.18, 2019, TB Alliance, and Mylan N.V. announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).

For the fourth Quarter of 2018, the company reported Total revenues of $3.08 billion, down 5% compared to the prior year period. Aadjusted EPS came to $1.30, down 9% over the prior year period.

For the full Year of 2018, the company reported total revenues of $11.43 billion, down 4% compared to the prior year. Adjusted EPS of $4.58, up slightly when compared to the prior year.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

MYL’s strengths can be seen in its better profitability and better effieicncy compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic oscillator. The RSI(14) stands at 45.45 with positive bias. We rate We rate Mylan N.V. (MYL) a STRONG BUY.